At NYU Langone’s Center for Psychedelic Medicine, our researchers are conducting several clinical trials which are currently recruiting participants. Please see below to learn more about our clinical trials that are actively enrolling.

To learn more about upcoming studies, please visit our research page, or to express interest in participating in a trial that is not yet recruiting, please fill out the Research Interest Survey.

Psilocybin for Smoking Cessation

The purpose of this study is to assess the potential therapeutic benefit of psilocybin-assisted psychotherapy for smoking cessation among daily smokers. Participants in this study will be randomly assigned to either the psilocybin-assisted psychotherapy group or control group. Individuals in the psilocybin-assisted group will receive two psilocybin sessions over approximately two weeks, and individuals in the control group will undergo the same sessions with niacin (vitamin B3) given instead of psilocybin. If you are interested in participating in this study, please fill out this short survey. A member of our team will be in touch if you qualify.

Psilocybin Therapy in Advanced Cancer

The purpose of this study is to assess the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of meaning and hope; fear of death) in advanced cancer (i.e., stage 3 or 4). Study medications will be administered in conjunction with brief psychotherapy that is designed to treat anxiety, depression, and existential distress in advanced cancer. Learn more about this study.

A Phase 3 Study: Psilocybin for the Treatment of Major Depressive Disorder

The purpose of this study is to see if the investigational drug, psilocybin, can help people with major depressive disorder (MDD). This study will evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between groups in change in depressive symptoms from Baseline to Day 43 post-dose. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo.

RE104 Safety and Efficacy-Study in Postpartum Depression

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo.

Neurobehavioral Mechanisms of Psilocybin-Assisted Treatment for Alcohol Use Disorder

The purpose of this research is to study the effects of the study drug, psilocybin, on alcohol addiction. This will be measured by studying the function of the brain, by using functional magnetic resonance imaging (fMRI). This research study will compare a high dose of psilocybin (30 mg) to inactive placebo.

Research Interest Survey

Are you interested in participating in a future research study at the Center for Psychedelic Medicine? Please complete our Research Interest Survey to provide your contact information as well as answer a few questions about yourself and types of studies you may be interested in.

If the information you provide indicates that you might qualify for a clinical research study at the center, a member of our team will follow up with you at your preferred contact method.